Abstract
Gross total resection, though proven to be effective, is often hindered by the notoriously challenging differentiation between malignant glioma and the surrounding edematous brain when using standard white light microscopy. Intraoperative imaging or neuronavigation by preoperative datasets deliver inconsistent results as they often fail to demonstrate tumor or resection borders reliably. With the introduction of the 5-aminolevulinic acid (5-ALA, Gliolan®) fluorescence microscopy, neurosurgeons command a highly specific biological tumor marker for malignant glioma resection, to help distinguish the vital tumor tissue from normal brain and improve the extent of tumor removal. Keywords: 5-aminolevulinic acid, Gliolan®, 5-ALA, fluorescence microscopy, malignant glioma, glioblastoma, protoporphyrin IX, fluorescence-guided surgery, temozolomide, positive predictive value (PPV), porphyria, hepatopathy, renal insufficiency, PpIX fluorescence
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
